Free CME from PeerView

Continuing Pharmacy Education (CPE) Activities

Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
StartThis activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
StartThis activity expired on December 9, 2024; credit is no longer available.
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes
Activity Description
Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and
TROP2, are an exciting new class of therapies that selectively deliver
cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented
the role of ADCs in the treatment of various solid tumors, motivating further
innovation to expand their use in other tumor types and disease settings. The
new ADC era brings hope to patients with unmet needs, and keeping current
with the latest advances, applying evidence to practice, mitigating adverse
events, and identifying patients eligible to received ADCs in practice and
clinical trials are more important than ever.
This PeerView educational activity, based on a recent live symposium, offers
expert guidance on how to interpret and apply the latest evidence on HER2-,
HER3-, TROP2-targeting, and other ADCs in the treatment of different solid
tumors. Strategies for decision-making and optimizing outcomes for patients
with cancer who may benefit from ADCs are also discussed, and case-based
clinical scenarios highlight the practical considerations related to using
ADCs in real-world care settings.
Target Audience
This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
- Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
- Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
- Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen
Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals
Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME
and OncLive.
Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial
interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
![]() |
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CE/CPE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 9, 2024; credit is no longer available.
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes
Activity Description
Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and
TROP2, are an exciting new class of therapies that selectively deliver
cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented
the role of ADCs in the treatment of various solid tumors, motivating further
innovation to expand their use in other tumor types and disease settings. The
new ADC era brings hope to patients with unmet needs, and keeping current
with the latest advances, applying evidence to practice, mitigating adverse
events, and identifying patients eligible to received ADCs in practice and
clinical trials are more important than ever.
This PeerView educational activity, based on a recent live symposium, offers
expert guidance on how to interpret and apply the latest evidence on HER2-,
HER3-, TROP2-targeting, and other ADCs in the treatment of different solid
tumors. Strategies for decision-making and optimizing outcomes for patients
with cancer who may benefit from ADCs are also discussed, and case-based
clinical scenarios highlight the practical considerations related to using
ADCs in real-world care settings.
Target Audience
This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
- Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
- Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
- Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen
Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals
Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME
and OncLive.
Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial
interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
![]() |
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CE/CPE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
StartThis activity expired on November 9, 2024; credit is no longer available.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes
Activity Description
The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
- Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
- Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 9, 2024; credit is no longer available.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes
Activity Description
The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
- Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
- Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
StartThis activity expired on November 26, 2024; credit is no longer available.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
- Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
- Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics
Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite,
A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis
Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.;
and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi
Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio,
Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly;
and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 26, 2024; credit is no longer available.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
- Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
- Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics
Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite,
A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis
Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.;
and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi
Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio,
Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly;
and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
StartThis activity expired on November 6, 2024; credit is no longer available.
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
Media: Enduring Material
Activity Release Date: October 7, 2023
Activity Expiration Date: November 6, 2024
Time to Complete Activity: 75 minutes
Activity Description
Advances in the understanding of the pathogenesis of generalized
myasthenia gravis (gMG), a rare, chronic autoimmune disorder, have led to the
development of new therapeutics that more selectively address the underlying
disease process compared with traditional therapies that often left patients
with substantial disease and treatment burden. These newer treatments include
Fc receptor (FcRn) inhibitors that increase immunoglobulin G (IgG)
degradation, leading to reduced levels of autoreactive IgG antibodies via
differing mechanisms of action and modes of delivery, including intravenous
infusion and subcutaneous injection.
In this PeerView “Candid Conversations and Clinical Consults” activity, a
neurologist, a clinical pharmacist, and an infusion nurse guide participants
through a case-based look at the evolving gMG treatment landscape. The
faculty share their expertise and put gMG management into practical context
through panel discussions that reflect their unique professional perspectives
as members of the gMG care team.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurse practitioners, pharmacists, infusion nurses, and other clinicians involved in the management of patients with myasthenia gravis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Assess how the safety, efficacy, and tolerability data related to newer treatment options for generalized myasthenia gravis (gMG) compare with the corresponding data for traditionally used therapies
- Demonstrate understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
- Implement safe, individualized administration protocols for patients using FcRn-modulating therapy, with consideration for proper infusion procedures, premedications, vaccinations, and treatment cycle timing
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
James F. Howard Jr., MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx;
Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc;
Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S;
Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB
Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and
Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx;
Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La
Roche Ltd; and Zai Lab.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.;
Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company
Limited.
Faculty/Planner
Claire Spahn, PharmD, BCPS
Clinical Pharmacist in Neurology
Stanford Neuroscience Health Center
Stanford, California
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-057-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 6, 2024; credit is no longer available.
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
Media: Enduring Material
Activity Release Date: October 7, 2023
Activity Expiration Date: November 6, 2024
Time to Complete Activity: 75 minutes
Activity Description
Advances in the understanding of the pathogenesis of generalized
myasthenia gravis (gMG), a rare, chronic autoimmune disorder, have led to the
development of new therapeutics that more selectively address the underlying
disease process compared with traditional therapies that often left patients
with substantial disease and treatment burden. These newer treatments include
Fc receptor (FcRn) inhibitors that increase immunoglobulin G (IgG)
degradation, leading to reduced levels of autoreactive IgG antibodies via
differing mechanisms of action and modes of delivery, including intravenous
infusion and subcutaneous injection.
In this PeerView “Candid Conversations and Clinical Consults” activity, a
neurologist, a clinical pharmacist, and an infusion nurse guide participants
through a case-based look at the evolving gMG treatment landscape. The
faculty share their expertise and put gMG management into practical context
through panel discussions that reflect their unique professional perspectives
as members of the gMG care team.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurse practitioners, pharmacists, infusion nurses, and other clinicians involved in the management of patients with myasthenia gravis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Assess how the safety, efficacy, and tolerability data related to newer treatment options for generalized myasthenia gravis (gMG) compare with the corresponding data for traditionally used therapies
- Demonstrate understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
- Implement safe, individualized administration protocols for patients using FcRn-modulating therapy, with consideration for proper infusion procedures, premedications, vaccinations, and treatment cycle timing
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
James F. Howard Jr., MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx;
Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc;
Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S;
Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB
Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and
Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx;
Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La
Roche Ltd; and Zai Lab.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.;
Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company
Limited.
Faculty/Planner
Claire Spahn, PharmD, BCPS
Clinical Pharmacist in Neurology
Stanford Neuroscience Health Center
Stanford, California
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-057-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
StartThis activity expired on October 28, 2024; credit is no longer available.
Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
Media: Enduring Material
Activity Release Date: September 29, 2023
Activity Expiration Date: October 28, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and hematologists, and other clinicians involved in the management of patients with MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans
- Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS
- Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia
- Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Beverly and George Rawlings Director of Hematology Research
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee
Michael R. Savona, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI
BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation;
Ryvu Therapeutics; and Sierra Oncology, Inc.
Grant/Research Support from ALX Oncology Inc.; Astex
Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in Empath Biosciences; Karyopharm and Ryvu
Therapeutics.
Other Financial or Material Support from Astex Pharmaceuticals for
travel grant.
Co-Chair/Planner
Andrew M. Brunner, MD
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Andrew M. Brunner, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acceleron Pharma, Inc.; Bristol Myers
Squibb; Gilead Sciences, Inc.; Keros Therapeutics; LAVA Therapeutics;
Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Taiho
Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company
Limited.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-063-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/28/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 28, 2024; credit is no longer available.
Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
Media: Enduring Material
Activity Release Date: September 29, 2023
Activity Expiration Date: October 28, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and hematologists, and other clinicians involved in the management of patients with MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans
- Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS
- Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia
- Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Beverly and George Rawlings Director of Hematology Research
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee
Michael R. Savona, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI
BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation;
Ryvu Therapeutics; and Sierra Oncology, Inc.
Grant/Research Support from ALX Oncology Inc.; Astex
Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in Empath Biosciences; Karyopharm and Ryvu
Therapeutics.
Other Financial or Material Support from Astex Pharmaceuticals for
travel grant.
Co-Chair/Planner
Andrew M. Brunner, MD
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Andrew M. Brunner, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acceleron Pharma, Inc.; Bristol Myers
Squibb; Gilead Sciences, Inc.; Keros Therapeutics; LAVA Therapeutics;
Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Taiho
Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company
Limited.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-063-H01-P
Type of Activity: Application
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/28/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
StartThis activity expired on September 13, 2024; credit is no longer available.
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
- Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
- Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
- Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama
Boni Elizabeth Elewski, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO
Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho
Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB,
Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB,
Inc.
Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York
Mark Lebwohl, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC;
AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics,
Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer
Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara
Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas,
LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.;
Facilitation of International Dermatology Education; Forte Biosciences,
Inc.; Foundation for Research and Education in Dermatology; Galderma;
Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji
Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous
Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi
Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho
Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on September 13, 2024; credit is no longer available.
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
- Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
- Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
- Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama
Boni Elizabeth Elewski, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO
Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho
Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB,
Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB,
Inc.
Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York
Mark Lebwohl, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC;
AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics,
Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer
Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara
Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas,
LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.;
Facilitation of International Dermatology Education; Forte Biosciences,
Inc.; Foundation for Research and Education in Dermatology; Galderma;
Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji
Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous
Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi
Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho
Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge
Physician Assistants
![]() |
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
StartThis activity expired on October 6, 2024; credit is no longer available.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
- Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
- Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
- Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy E. DeZern, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou
Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; and Sobi.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
- Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
- Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
- Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy E. DeZern, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou
Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; and Sobi.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
StartThis activity expired on October 6, 2024; credit is no longer available.
Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM
- Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations
- Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-090-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda
Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.
Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers
Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.;
Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and
Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.;
Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen
Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision
BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM
- Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations
- Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-090-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda
Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.
Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers
Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.;
Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and
Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.;
Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen
Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision
BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
StartThis activity expired on October 6, 2024; credit is no longer available.
Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Innovative therapeutics have transformed the management of chronic
lymphocytic leukemia (CLL) and allowed patients a greater range of treatment
options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have
demonstrated efficacy in a wide variety of treatment settings, and newer,
non-covalent BTKi are poised to overcome long-standing therapeutic standards.
Do you have the tools needed to “level up” your practice?
Find out in this “Clinical Consults” activity based on a symposium that was
recorded at the Society of Hematologic Oncology’s 11th Annual Meeting.
Throughout this program, a panel of leading CLL experts use conversational,
case-based dialogue to provide guidance on integrating modern therapeutics
anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent
BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen
your therapeutic skills, and reach the next level of CLL care today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics
- Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL
- Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-089-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr.
Elihu Estey
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director, Leukemia
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas
William G. Wierda, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Accutar Biotech;
Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals;
Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.
(ended); Novartis Pharmaceuticals Corporation; Numab Therapeutics AG; Nurix
Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis
Pharmaceuticals, Inc. (ended); and Xencor.
Other Financial or Material Support for Nonrelevant Financial
Relationship: National Comprehensive Cancer Network (Chair & CLL); NIH/NCI
under award number P30 CA016672 and used MDACC Cancer Center Support Grant
(CCSG) shared resources.
Co-Chair/Planner
Nicole Lamanna, MD
Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.;
Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics,
Inc.
Faculty/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/LOXO Oncology;
Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene,
Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research
funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Dava
Oncology; Curio Science; Hemotherapy and Cellular Therapy (ABHH);
Massachusetts Medical Society; MJH Life Sciences; Intellisphere LLC; Phillips
Group Oncology Communications; and VJHemOnc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Innovative therapeutics have transformed the management of chronic
lymphocytic leukemia (CLL) and allowed patients a greater range of treatment
options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have
demonstrated efficacy in a wide variety of treatment settings, and newer,
non-covalent BTKi are poised to overcome long-standing therapeutic standards.
Do you have the tools needed to “level up” your practice?
Find out in this “Clinical Consults” activity based on a symposium that was
recorded at the Society of Hematologic Oncology’s 11th Annual Meeting.
Throughout this program, a panel of leading CLL experts use conversational,
case-based dialogue to provide guidance on integrating modern therapeutics
anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent
BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen
your therapeutic skills, and reach the next level of CLL care today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics
- Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL
- Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-089-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr.
Elihu Estey
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director, Leukemia
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas
William G. Wierda, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Accutar Biotech;
Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals;
Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.
(ended); Novartis Pharmaceuticals Corporation; Numab Therapeutics AG; Nurix
Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis
Pharmaceuticals, Inc. (ended); and Xencor.
Other Financial or Material Support for Nonrelevant Financial
Relationship: National Comprehensive Cancer Network (Chair & CLL); NIH/NCI
under award number P30 CA016672 and used MDACC Cancer Center Support Grant
(CCSG) shared resources.
Co-Chair/Planner
Nicole Lamanna, MD
Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.;
Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics,
Inc.
Faculty/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/LOXO Oncology;
Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene,
Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research
funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Dava
Oncology; Curio Science; Hemotherapy and Cellular Therapy (ABHH);
Massachusetts Medical Society; MJH Life Sciences; Intellisphere LLC; Phillips
Group Oncology Communications; and VJHemOnc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
StartThis activity expired on October 6, 2024; credit is no longer available.
Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML
- Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML
- Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype
- Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-091-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals, Inc.;
Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Kite, A Gilead
Company; Novartis Pharmaceuticals Corporation; Pfizer; Servier
Pharmaceuticals LLC; Shattuck Labs, Inc.; Stemline Therapeutics/Menarini
Group; Syndax Pharmaceuticals Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie; Amgen Inc.; Astellas Pharma
Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Fate Therapeutics;
Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi
Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; Kite, A Gilead Company; NovImmune
SA; Pfizer; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and
TrovaGene, Inc. Research funding goes to institution.
Co-Chair/Planner
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Argenx;
AstraZeneca; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb;
Caribou Biosciences; Celgene Corporation; Daiichi Sankyo, Inc.; Ellipses
Pharma; F. Hoffmann-La Roche AG; GlaxoSmithKline; Janssen Pharmaceuticals,
Inc; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Molecular
Partners; Novartis Pharmaceuticals Corporation; Pfizer; Syndax
Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited (IRC Chair); and
Telix Pharma.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML
- Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML
- Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype
- Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-091-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals, Inc.;
Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Kite, A Gilead
Company; Novartis Pharmaceuticals Corporation; Pfizer; Servier
Pharmaceuticals LLC; Shattuck Labs, Inc.; Stemline Therapeutics/Menarini
Group; Syndax Pharmaceuticals Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie; Amgen Inc.; Astellas Pharma
Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Fate Therapeutics;
Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi
Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; Kite, A Gilead Company; NovImmune
SA; Pfizer; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and
TrovaGene, Inc. Research funding goes to institution.
Co-Chair/Planner
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Argenx;
AstraZeneca; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb;
Caribou Biosciences; Celgene Corporation; Daiichi Sankyo, Inc.; Ellipses
Pharma; F. Hoffmann-La Roche AG; GlaxoSmithKline; Janssen Pharmaceuticals,
Inc; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Molecular
Partners; Novartis Pharmaceuticals Corporation; Pfizer; Syndax
Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited (IRC Chair); and
Telix Pharma.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
StartThis activity expired on August 2, 2024; credit is no longer available.
Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
Media: Enduring Material
Activity Release Date: August 3, 2023
Activity Expiration Date: August 2, 2024
Time to Complete Activity:
- 45 minutes
Activity Description
In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care.
Target Audience
This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease providers, HIV workforce professionals, and other clinicians involved in the care of patients with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Babafemi O. Taiwo, MBBS
Chief of Infectious Diseases in the Department of Medicine
Gene Stollerman Professor of Medicine
Professor of Medicine (Infectious Diseases)
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Babafemi O. Taiwo, MBBS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Johnson &
Johnson; Merck & Co., Inc.; and ViiV Healthcare.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners
This activity has been developed in partnership with HealthHIV
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-047-H02-P
Type of Activity:
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on August 2, 2024; credit is no longer available.
Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
Media: Enduring Material
Activity Release Date: August 3, 2023
Activity Expiration Date: August 2, 2024
Time to Complete Activity:
- 45 minutes
Activity Description
In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care.
Target Audience
This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease providers, HIV workforce professionals, and other clinicians involved in the care of patients with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Babafemi O. Taiwo, MBBS
Chief of Infectious Diseases in the Department of Medicine
Gene Stollerman Professor of Medicine
Professor of Medicine (Infectious Diseases)
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Babafemi O. Taiwo, MBBS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Johnson &
Johnson; Merck & Co., Inc.; and ViiV Healthcare.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners
This activity has been developed in partnership with HealthHIV
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-047-H02-P
Type of Activity:
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
StartThis activity expired on August 1, 2024; credit is no longer available.
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.
Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
- Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
- Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute
Columbus, Ohio
Jennifer Woyach, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene;
Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave
Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics;
Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.;
Schrödinger, Inc.; and Verastem Oncology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
![]() |
The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on August 1, 2024; credit is no longer available.
Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.
Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
- Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
- Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute
Columbus, Ohio
Jennifer Woyach, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene;
Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave
Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics;
Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.;
Schrödinger, Inc.; and Verastem Oncology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
![]() |
The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
StartThis activity expired on June 28, 2024; credit is no longer available.
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes
Activity Description
In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.
Target Audience
This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland
Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co.,
Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC
Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
David Martin
Patient/Advocate
David Martin has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Shawnte' Spriggs
Patient/Advocate
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on June 28, 2024; credit is no longer available.
Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider
Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes
Activity Description
In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.
Target Audience
This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland
Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co.,
Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC
Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
David Martin
Patient/Advocate
David Martin has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Shawnte' Spriggs
Patient/Advocate
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
StartThis activity expired on July 2, 2024; credit is no longer available.
New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
Activity Description and Educational Objectives
Recent research and improved understanding of the pathogenesis of multiple
sclerosis (MS) has led to the development of multiple biomarkers and imaging
modalities that can improve clinicians’ ability to individualize therapy
through more effective monitoring of disease progression and treatment
response. The promise of eventually arriving at data-driven personalized
care—coupled with the number of available and emerging therapies for MS
treatment—makes it more important than ever that clinicians remain up-to-date
on advances in biomarkers and imaging approaches, as well as shared
decision-making strategies.
In this activity, based on a recent live symposium, MS experts cover the
latest data on these new and emerging biomarkers for MS management. Using
examples from their own practice, the panelists also discuss ways to
incorporate these biomarker findings into individualized treatment decisions
to empower patients and improve treatment outcomes.
Upon completion of this activity, participants should be better able to:
- Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
- Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
- Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive
CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful
completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada
Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers
Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis
Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada;
and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono
Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and
Sanofi/Genzyme Canada Inc.
Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals
Corporation.
Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado
Kathleen M. Costello, RN, MS, NP, MSCN, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support


Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6939-23-T.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on July 2, 2024; credit is no longer available.
New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now
Activity Description and Educational Objectives
Recent research and improved understanding of the pathogenesis of multiple
sclerosis (MS) has led to the development of multiple biomarkers and imaging
modalities that can improve clinicians’ ability to individualize therapy
through more effective monitoring of disease progression and treatment
response. The promise of eventually arriving at data-driven personalized
care—coupled with the number of available and emerging therapies for MS
treatment—makes it more important than ever that clinicians remain up-to-date
on advances in biomarkers and imaging approaches, as well as shared
decision-making strategies.
In this activity, based on a recent live symposium, MS experts cover the
latest data on these new and emerging biomarkers for MS management. Using
examples from their own practice, the panelists also discuss ways to
incorporate these biomarker findings into individualized treatment decisions
to empower patients and improve treatment outcomes.
Upon completion of this activity, participants should be better able to:
- Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
- Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
- Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive
CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful
completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada
Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers
Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis
Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada;
and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono
Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and
Sanofi/Genzyme Canada Inc.
Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals
Corporation.
Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado
Kathleen M. Costello, RN, MS, NP, MSCN, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support


Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6939-23-T.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
StartThis activity expired on July 1, 2024; credit is no longer available.
Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
Activity Format: Internet Enduring Activity
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Time to Complete Activity: 60 minutes
Program Overview
Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs).
Target Audience
This activity has been designed to meet the educational needs of cardiologists, internists, lipid specialists, nurses, pharmacists, and other clinicians involved in the management of hyperlipidemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD
- Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers
- Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance
and submission of the activity evaluation form. Partial credit may be awarded
for ACPE credit. A statement of credit will be available upon completion of
an online evaluation/claimed credit form at www.lipid.org/cme. The deadline
to claim credit is July 1, 2024.
For Pharmacists: Upon receipt of the completed activity evaluation
form, transcript information will be available at www.mycpemonitor.net within
4 weeks.
*IMPORTANT* Pharmacists MUST request credit before July 1, 2024. Credit
requested after this date will be subject to a fee by the accreditation
board.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Credit Designation
CME Credit Provided by the National Lipid Association
![]() |
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physician Credit Designation Statement
The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CME Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 CME CreditTM from organizations accredited by ACCME.
Pharmacists
This activity has been approved for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA0007192-9999-23-007-H01-P (Knowledge).
Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
For the advanced practice nurse, pharmacotherapy hours will be calculated on
your certificate.
Faculty
Co-Chair & Presenter
P. Barton Duell, MD
Professor of Medicine
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Oregon Health & Science University
Center for Preventive Cardiology
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes and Clinical Nutrition
Portland, Oregon
P. Barton Duell, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc./Ionis
Pharmaceuticals; Esperion Therapeutics, Inc.; Kaneka Medical America LLC;
Novo Nordisk Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from Regeneron Pharmaceuticals Inc.;
REGENXBIO Inc.; and Retrophin/Travere Therapeutics, Inc.
Co-Chair & Presenter
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC, has a financial
interest/relationship or affiliation in the form of:
Grant/Research Support from Akcea Pharmaceuticals.
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of the NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by the NLA prior to accreditation of the activity. The NLA planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
Copyright © 2000-2023, PeerView
This activity expired on July 1, 2024; credit is no longer available.
Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
Activity Format: Internet Enduring Activity
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Time to Complete Activity: 60 minutes
Program Overview
Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs).
Target Audience
This activity has been designed to meet the educational needs of cardiologists, internists, lipid specialists, nurses, pharmacists, and other clinicians involved in the management of hyperlipidemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD
- Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers
- Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance
and submission of the activity evaluation form. Partial credit may be awarded
for ACPE credit. A statement of credit will be available upon completion of
an online evaluation/claimed credit form at www.lipid.org/cme. The deadline
to claim credit is July 1, 2024.
For Pharmacists: Upon receipt of the completed activity evaluation
form, transcript information will be available at www.mycpemonitor.net within
4 weeks.
*IMPORTANT* Pharmacists MUST request credit before July 1, 2024. Credit
requested after this date will be subject to a fee by the accreditation
board.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Credit Designation
CME Credit Provided by the National Lipid Association
![]() |
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physician Credit Designation Statement
The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CME Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 CME CreditTM from organizations accredited by ACCME.
Pharmacists
This activity has been approved for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA0007192-9999-23-007-H01-P (Knowledge).
Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
For the advanced practice nurse, pharmacotherapy hours will be calculated on
your certificate.
Faculty
Co-Chair & Presenter
P. Barton Duell, MD
Professor of Medicine
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Oregon Health & Science University
Center for Preventive Cardiology
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes and Clinical Nutrition
Portland, Oregon
P. Barton Duell, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc./Ionis
Pharmaceuticals; Esperion Therapeutics, Inc.; Kaneka Medical America LLC;
Novo Nordisk Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from Regeneron Pharmaceuticals Inc.;
REGENXBIO Inc.; and Retrophin/Travere Therapeutics, Inc.
Co-Chair & Presenter
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon
Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC, has a financial
interest/relationship or affiliation in the form of:
Grant/Research Support from Akcea Pharmaceuticals.
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of the NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by the NLA prior to accreditation of the activity. The NLA planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
Copyright © 2000-2023, PeerView

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
StartThis activity expired on June 30, 2024; credit is no longer available.
Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Optimal management of multiple sclerosis (MS) requires selecting
medications that safely and effectively target different aspects of
pathophysiology and offer choices in administration, risk/benefit balance,
and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an
emerging class of disease-modifying therapies that affect processes mediated
by B cells and myeloid cells, which are contributors to the inflammation and
neurodegeneration that drive MS. BTK inhibitors are a novel class in MS
management with four agents currently in phase 3 trials. As such, clinicians
must remain up to date with the latest data on the rationale for their use
and trial findings on the efficacy, safety, and tolerability of this
promising line of treatment.
At a recent PeerView live event, MS experts shared relevant stories from
their practice to highlight the rationale for the use of BTK inhibitors in
MS, as well as perspectives on potential applications in clinical care and
the latest data from clinical trials on BTK inhibition.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
- Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
- Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics,
Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen
Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC;
Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and
Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis
Pharmaceuticals Corporation (paid to institution).
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La
Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada
Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on June 30, 2024; credit is no longer available.
Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition
Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Optimal management of multiple sclerosis (MS) requires selecting
medications that safely and effectively target different aspects of
pathophysiology and offer choices in administration, risk/benefit balance,
and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an
emerging class of disease-modifying therapies that affect processes mediated
by B cells and myeloid cells, which are contributors to the inflammation and
neurodegeneration that drive MS. BTK inhibitors are a novel class in MS
management with four agents currently in phase 3 trials. As such, clinicians
must remain up to date with the latest data on the rationale for their use
and trial findings on the efficacy, safety, and tolerability of this
promising line of treatment.
At a recent PeerView live event, MS experts shared relevant stories from
their practice to highlight the rationale for the use of BTK inhibitors in
MS, as well as perspectives on potential applications in clinical care and
the latest data from clinical trials on BTK inhibition.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
- Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
- Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics,
Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen
Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC;
Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and
Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis
Pharmaceuticals Corporation (paid to institution).
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La
Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada
Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme
Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
StartThis activity expired on May 18, 2024; credit is no longer available.
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
- Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
- Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina
Patrick A. Flume, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi
USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis
Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck &
Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals
Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata
Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen
Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals;
and Vertex Pharmaceuticals Incorporated.
Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado
Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Susan Palmer
Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Insmed.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 18, 2024; credit is no longer available.
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
- Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
- Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina
Patrick A. Flume, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi
USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis
Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck &
Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals
Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata
Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen
Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals;
and Vertex Pharmaceuticals Incorporated.
Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado
Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Susan Palmer
Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Insmed.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
StartThis activity expired on May 10, 2024; credit is no longer available.
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
Media: Enduring Material
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Time to Complete Activity: 60 minutes
Activity Description
An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis.
Target Audience
This activity has been designed to meet the educational needs of US and EU neurologists, including neuromuscular and neuroimmunology specialists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the care of patients with gMG.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life
- Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices
- Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outcomes measures of treatment response and adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Director of the Neuromuscular Section
Division of Neurology
University of Toronto
University Health Network
Toronto, Ontario, Canada
Vera Bril, BSc, FRCPC, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; F. Hoffmann-La Roche Ltd; Ionis Pharmaceuticals;
Immunovant, Inc.; Janssen Inc.; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services, Inc.; Novo Nordisk
Inc.; Octapharma Canada Inc.; Powell Mansfield Inc.; Pfizer;
Sanofi; Takeda Pharmaceutical Company; and UCB Canada Inc.
Grant/Research Support from Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; Ionis Pharmaceuticals; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services; Octapharma Canada Inc.; Takeda
Pharmaceutical Company; and UCB Canada Inc.
Speaker for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals,
Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; and CSL
Behring.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion S.p.A; Koru
Pharmaceuticals Co., LTD.; Octapharma USA, Inc.; and Takeda Pharmaceuticals
U.S.A., Inc.
Faculty/Planner
Francesco Saccà, MD
Associate Professor of Neurology
NSRO Department
University "Federico II"
Naples, Italy
Francesco Saccà, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx;
Lexeo Therapeutics, Inc.; Novartis AG; Reata Pharmaceuticals, Inc.; and
Takeda Italia S.p.A.
Speaker for Alexion Pharmaceuticals, Inc. and Novartis AG.
Patient/Planner
Kaitlin Stockwell Masters
Kaitlin Stockwell Masters has a financial interest/relationship or
affiliation in the form of:
Speaker for argenx.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-040-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 10, 2024; credit is no longer available.
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
Media: Enduring Material
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Time to Complete Activity: 60 minutes
Activity Description
An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis.
Target Audience
This activity has been designed to meet the educational needs of US and EU neurologists, including neuromuscular and neuroimmunology specialists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the care of patients with gMG.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life
- Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices
- Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outcomes measures of treatment response and adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Director of the Neuromuscular Section
Division of Neurology
University of Toronto
University Health Network
Toronto, Ontario, Canada
Vera Bril, BSc, FRCPC, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; F. Hoffmann-La Roche Ltd; Ionis Pharmaceuticals;
Immunovant, Inc.; Janssen Inc.; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services, Inc.; Novo Nordisk
Inc.; Octapharma Canada Inc.; Powell Mansfield Inc.; Pfizer;
Sanofi; Takeda Pharmaceutical Company; and UCB Canada Inc.
Grant/Research Support from Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; Ionis Pharmaceuticals; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services; Octapharma Canada Inc.; Takeda
Pharmaceutical Company; and UCB Canada Inc.
Speaker for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals,
Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; and CSL
Behring.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion S.p.A; Koru
Pharmaceuticals Co., LTD.; Octapharma USA, Inc.; and Takeda Pharmaceuticals
U.S.A., Inc.
Faculty/Planner
Francesco Saccà, MD
Associate Professor of Neurology
NSRO Department
University "Federico II"
Naples, Italy
Francesco Saccà, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx;
Lexeo Therapeutics, Inc.; Novartis AG; Reata Pharmaceuticals, Inc.; and
Takeda Italia S.p.A.
Speaker for Alexion Pharmaceuticals, Inc. and Novartis AG.
Patient/Planner
Kaitlin Stockwell Masters
Kaitlin Stockwell Masters has a financial interest/relationship or
affiliation in the form of:
Speaker for argenx.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-040-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView

Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care
StartThis activity expired on May 25, 2024; credit is no longer available.
Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care
Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 60 minutes
Activity Description
The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process.
Target Audience
This activity has been designed to meet the educational needs of internal medicine physicians, family medicine physicians, geriatricians, advanced practice clinicians, nurses, pharmacists, psychologists, and other clinicians involved in the assessment and care of patients with or at risk for Alzheimer's disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD
- Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns
- Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Anna Chodos, MD, MPH
Associate Professor of Medicine
Division of Geriatrics and Division of General Internal Medicine
Zuckerberg San Francisco General Hospital
Department of Medicine
University of California
San Francisco, California
Anna Chodos, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Ian Neel, MD
Associate Clinical Professor of Medicine
Medical Director, Geriatric Medicine Consult Service
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California
Ian Neel, MD, has a financial interest/relationship or affiliation in the
form of:
Consultant and/or Advisor for Centene Corporation/Health Net
Pharmacy and Therapeutics Committee.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-022-H01-P
Type of Activity: Application
Psychologists
![]() |
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/APA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 25, 2024; credit is no longer available.
Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care
Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 60 minutes
Activity Description
The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process.
Target Audience
This activity has been designed to meet the educational needs of internal medicine physicians, family medicine physicians, geriatricians, advanced practice clinicians, nurses, pharmacists, psychologists, and other clinicians involved in the assessment and care of patients with or at risk for Alzheimer's disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD
- Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns
- Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Anna Chodos, MD, MPH
Associate Professor of Medicine
Division of Geriatrics and Division of General Internal Medicine
Zuckerberg San Francisco General Hospital
Department of Medicine
University of California
San Francisco, California
Anna Chodos, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Ian Neel, MD
Associate Clinical Professor of Medicine
Medical Director, Geriatric Medicine Consult Service
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California
Ian Neel, MD, has a financial interest/relationship or affiliation in the
form of:
Consultant and/or Advisor for Centene Corporation/Health Net
Pharmacy and Therapeutics Committee.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-022-H01-P
Type of Activity: Application
Psychologists
![]() |
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. |
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/APA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView